Roivant Sciences (ROIV) traded sharply higher after its subsidiary Immunovant (IMVT) posted initial results from a Phase 2 trial evaluating its lead asset IMVT-1402 in rheumatoid arthritis, an ...
Roivant financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Good day, and welcome to the Brepocitinib Program Expansion and Batoclimab update. [Operator Instructions] Please note, this call is being recorded. I would now like to turn the call over to Stephanie ...
Shares of Roivant Sciences (NASDAQ: ROIV) are soaring 11.4% higher as of 11:19 a.m. ET on Wednesday. The big gain came after Roivant and Priovant Therapeutics announced positive results from a ...
BASEL, Switzerland & LONDON & NEW YORK--(BUSINESS WIRE)--Roivant (Nasdaq: ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Immunovant develops monoclonal antibody therapeutics, with batoclimab as its lead candidate targeting autoimmune diseases such as myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results